AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37506599
Drug: Lacticaseibacillus paracasei
RxNorm normalized name: Lacticaseibacillus paracasei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacticaseibacillus paracasei 8700:2 (10 billion CFU) daily for 12 weeks with ideal compliance
Trial: 37507274
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of BNT162b2 mRNA COVID-19 vaccine
Trial: 37507274
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (unvaccinated or vaccinated with other vaccines)
Trial: 37507392
Drug: Low-dose ARVAC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ARVAC CG
Trial: 37507392
Drug: High-dose ARVAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ARVAC CG
Trial: 37507425
Drug: Ruxolitinib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (10 mg twice daily for a median of 14 days)
Trial: 37507543
Drug: Trastuzumab, lapatinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab, lapatinib, or both in combination with chemotherapy
Trial: 37507657
Drug: Galunisertib 150
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galunisertib 150 mg twice daily (14 days on/14 days off) plus nivolumab 3 mg/kg (IV every 2 weeks)
Trial: 37507667
Drug: Volunteer-led online
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteer-led online group seated strength exercises using resistance bands, once weekly for 6 months
Trial: 37507763
Drug: Nitrate-replete beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-replete beetroot juice (400 mg nitrate/day)
Trial: 37508992
Drug: Transcranial Direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial Direct Current Stimulation (tDCS) coupled with language therapy
Trial: 37509349
Drug: Canady Helios
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canady Helios Cold Plasma (CHCP) treatment during surgical resection
Trial: 37509587
Drug: GABA/GAD65-alum treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA/GAD65-alum treatment
Trial: 37510953
Drug: Single-strain probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-strain probiotic formulations
Trial: 37511562
Drug: CAR-T therapy
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T therapy (Yescarta™)
Trial: 37515050
Drug: Single booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single booster dose
Trial: 37515194
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of probenecid every 12 h for five days
Trial: 37515194
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of probenecid every 12 h for five days
Trial: 37515459
Drug: Normobaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normobaric oxygen (NBO) therapy within 6 hours of symptom onset
Trial: 37515459
Drug: Normobaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normobaric oxygen (NBO) therapy
Trial: 37516125
Drug: Atogepant 30
RxNorm normalized name: atogepant 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atogepant 30 mg twice a day
Trial: 38364831
Drug: Atogepant 60
RxNorm normalized name: atogepant 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atogepant 60 mg once a day
Trial: 37516163
Drug: CBT-I (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-I (Cognitive Behavioral Therapy for Insomnia)
Trial: 37516163
Drug: CBT-D (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-D (Cognitive Behavioral Therapy for Depression)
Trial: 37516163
Drug: CBT-I +
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-I + D (sequential intervention)
Trial: 37516163
Drug: CBT-D +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-D + I (sequential intervention)
Trial: 37516818
Drug: EGFR TKI
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR TKI treatment
Trial: 37516867
Drug: UCPVax vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCPVax vaccine at 0.5 mg subcutaneously combined with atezolizumab (1200 mg IV infusion) and bevacizumab (15 mg/kg IV infusion) every 3 weeks.
Trial: 37516867
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg IV infusion) and bevacizumab (15 mg/kg IV infusion) every 3 weeks.
Trial: 37517422
Drug: OVX836 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OVX836 180 μg
Trial: 37517422
Drug: OVX836 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OVX836 300 μg
Trial: 37517422
Drug: OVX836 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OVX836 480 μg
Trial: 37517579
Drug: Stent placement
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stent placement with best medical therapy (BMT)
Trial: 37517875
Drug: RRMM treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRMM treatments
Trial: 37518058
Drug: Supplemental enteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental enteral protein (1.2 g/kg/day) starting from ICU day 5 until ICU discharge or ICU day 90
Trial: 37518058
Drug: Standard enteral
RxNorm normalized name: Standard enteral formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard enteral nutrition formula (0.8-1.2 g/kg/day) without supplemental protein
Trial: 37518058
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups receive primary enteral formula with a maximum protein of 1.2 g/kg/day
Trial: 37518060
Drug: Apatinib 500
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 500 mg QD on days 1-4; Gefitinib 250 mg QD on days 5-15, combined with Apatinib 500 mg QD on days 12-15.
Trial: 37518076
Drug: High-dose docosahexaenoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose docosahexaenoic acid (DHA) enteral supplementation during the neonatal period
Trial: 37518076
Drug: High-dose DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DHA enteral supplementation
Trial: 37518082
Drug: Optokinetic stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optokinetic stimulation (OKS) - 2 weekly sessions for 10 weeks using virtual reality glasses to project OKS at a preset speed.
Trial: 37518082
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment - virtual reality video without OKS.
Trial: 37518089
Drug: Colistin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin administered as colistin methanesulfonate (CMS) intravenously at standard dosing.
Trial: 37518975
Drug: Fecal elastase-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal elastase-1 (FE-1) levels >500 µg/g
Trial: 37519971
Drug: Regenerative endodontic
RxNorm normalized name: Regener-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regenerative endodontic therapy (RET) with modified triple antibiotic paste (mTAP)
Trial: 37519971
Drug: Regenerative endodontic
RxNorm normalized name: Regener-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regenerative endodontic therapy (RET) with Metapex™
Trial: 37520411
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg IV sotrovimab
Trial: 37521410
Drug: Hydrogen-rich coral
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen-rich coral calcium (HRCC) capsules (low, medium, and high doses)
Trial: 37521410
Drug: Hydrogen-rich coral
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen-rich coral calcium (HRCC) capsules
Trial: 37522330
Drug: Existing phototherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Existing phototherapy treatment
Trial: 37522415
Drug: Oxytocin 240
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin 240 IU inhaled
Trial: 37522415
Drug: Oxytocin 5
RxNorm normalized name: oxytocin 5 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin 5 IU intravenous
Trial: 37522415
Drug: Oxytocin 10
RxNorm normalized name: oxytocin 10 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin 10 IU intramuscular
Trial: 37522415
Drug: Blood collected
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood collected into lithium heparin (LH) tubes
Trial: 37522479
Drug: Modified rIX-FP
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified rIX-FP regimen at 40 IU/kg twice/week
Trial: 37523661
Drug: Lenvatinib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib (20 mg orally once daily) plus Pembrolizumab (200 mg intravenously every 3 weeks)
Trial: 37523661
Drug: Chemotherapy (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (doxorubicin or paclitaxel)
Trial: 37524096
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg oral daily for 54 weeks
Trial: 37524201
Drug: AZD7442 (tixagevimab/cilgavimab)
RxNorm normalized name: tixagevimab
DrugBank: AZD7442 (DB15787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7442 (tixagevimab/cilgavimab) 300 or 600 mg intramuscularly or 300 or 1000 mg intravenously
Trial: 37524230
Drug: RG6346 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG6346 at 1.5 mg/kg
Trial: 37524230
Drug: RG6346 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG6346 at 3.0 mg/kg
Trial: 37524230
Drug: RG6346 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG6346 at 6.0 mg/kg
Trial: 37525125
Drug: Virtual group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual group-based acceptance and commitment therapy (n=35)
Trial: 37525207
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted manual-assisted problem-solving intervention (CMAP) plus enhanced treatment as usual (E-TAU)
Trial: 37525207
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (E-TAU)
Trial: 37525278
Drug: Autologous leukocyte-
RxNorm normalized name: interferon alfa-3n,human leukocyte derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous leukocyte- and platelet-rich fibrin (L-PRF) membranes
Trial: 37525298
Drug: Treated participants
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treated participants (n=471, 62%) who self-reported accessing BN/BED treatment at some point in their lives
Trial: 37525298
Drug: Untreated participants
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Untreated participants (n=291, 38%) who never accessed treatment
Trial: 37525298
Drug: Individuals with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals with a history of inpatient or residential treatment
Trial: 37525298
Drug: Individuals with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals with outpatient treatment
Trial: 37525369
Drug: rabbit antithymocyte
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabbit antithymocyte globulin (2 × 1.5 mg/kg, postoperative days 0 and 1) and infliximab (5 mg/kg, postoperative day 2) followed by mycophenolate-free tacrolimus-based immunosuppression for 12 mo
Trial: 37525414
Drug: Laparoscopic-assisted transversus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic-assisted transversus abdominis plane block (L-TAPB)
Trial: 37525559
Drug: Supervised concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised concurrent exercise training program
Trial: 37525914
Drug: GJA4 variants
RxNorm normalized name: Carduus Marianus
DrugBank: Milk thistle (DB14375)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GJA4 variants (homozygous G variant, n = 84; 73%)
Trial: 37526149
Drug: Datopotamab deruxtecan
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Datopotamab deruxtecan (Dato-DXd) 6 mg/kg iv. every 3 weeks
Trial: 37526436
Drug: Multiple benzodiazepine
RxNorm normalized name: 1,2-Benzodiazepine
DrugBank: 1,2-Benzodiazepine (DB12537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple benzodiazepine receptor agonists
Trial: 37526856
Drug: Medium-dose MF/IND/GLY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose MF/IND/GLY
Trial: 37526856
Drug: High-dose ICS/LABA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ICS/LABA
Trial: 37526936
Drug: Orteronel 300
RxNorm normalized name: Orteronel
DrugBank: Orteronel (DB12066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orteronel 300 mg orally twice daily
Trial: 37526936
Drug: Bicalutamide 50
RxNorm normalized name: bicalutamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 50 mg orally daily
Trial: 37526937
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control (weekly health education telephone calls)
Trial: 37527479
Drug: Symptom remission
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom remission without antipsychotic medication
Trial: 37527726
Drug: Autologous cord
RxNorm normalized name: Autologous cord blood
DrugBank: Autologous cord blood (DB17926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous cord blood mononucleated cells (CBMNCs) delivered via intracoronary infusion during Norwood procedure, 4 doses of 15 mL each, without prior cryopreservation.
Trial: 37527730
Drug: Best Practices
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best Practices plus Financial Incentives and Nicotine Replacement Therapy (BP + FI + NRT)
Trial: 37527890
Drug: Peer-supported, WhatsApp-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-supported, WhatsApp-assisted lifestyle modification intervention delivered by a trained nutritionist for 1 year (3 days after baseline and then monthly).
Trial: 37527898
Drug: Bedtime use
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime use of antihypertensives
Trial: 37527898
Drug: Morning use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning use of antihypertensives
Trial: 37528405
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant (OAC) therapy including non-vitamin K antagonist oral anticoagulants (NOACs)
Trial: 37528410
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality (VR) exposure therapy
Trial: 37528500
Drug: Upadacitinib 30
RxNorm normalized name: upadacitinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 30 mg (rescue treatment)
Trial: 37528500
Drug: Upadacitinib (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib (7.5 mg, 15 mg, 30 mg)
Trial: 37529157
Drug: SHR-1802 (anti-LAG-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1802 (anti-LAG-3 monoclonal antibody) administered once every 21-day cycle, with doses escalating from 0.3 to 10 mg/kg
Trial: 37529919
Drug: Palbociclib with
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib with aromatase inhibitors
Trial: 37530622
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity (Cohort A, B, C)
Trial: 37530622
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg IV every 2 weeks until progression or unacceptable toxicity (Cohort C)
Trial: 37530627
Drug: JAKi monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAKi monotherapy (ruxolitinib, fedratinib, momelotinib)
Trial: 37530855
Drug: Anterior implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior implant treatment
Trial: 37530892
Drug: Furlow palatoplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furlow palatoplasty with buccal myomucosal flap (FPBF)
Trial: 37531083
Drug: LY3405105 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3405105 monotherapy (20 mg QD)
Trial: 37531083
Drug: LY3405105 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3405105 monotherapy (1-2 mg orally, escalated)
Trial: 37531083
Drug: LY3405105 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3405105 monotherapy (QD vs TIW dosing)
Trial: 37531083
Drug: LY3405105 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3405105 monotherapy (≥15 mg QD)
Trial: 37531130
Drug: Moderate-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity statin with ezetimibe (rosuvastatin, 10 mg with ezetimibe, 10 mg)
Trial: 37531657
Drug: Dose 4
RxNorm normalized name: Isordil Titradose 40mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 4 of vaccine at previously received antigen levels (100 or 200 μg)
Trial: 37531986
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of normal saline
Trial: 37531986
Drug: No administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No administration
Trial: 37532066
Drug: Three exercise
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three exercise sessions per week in adjunct to diet-induced weight loss
Trial: 37532066
Drug: Six exercise
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six exercise sessions per week in adjunct to diet-induced weight loss
Trial: 37532157
Drug: Parenteral treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Parenteral treprostinil
Trial: 37532250
Drug: Prednisolone eyedrops
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone eyedrops (tapering schedule)
Trial: 37532611
Drug: Tetravalent live
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent live attenuated dengue vaccine
Trial: 37532622
Drug: SYN120 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYN120 (100 mg/day)
Trial: 37532933
Drug: Next-generation probiotics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Next-generation probiotics, specific details on dosage and duration not available
Trial: 37532985
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of antipsychotics
Trial: 37533033
Drug: L-carnitine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (1 g of LC-L-tartrate and 3 g of leucine per day)
Trial: 37533033
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 g of leucine per day)
Trial: 37533058
Drug: tDCS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tDCS treatment (active)
Trial: 37533058
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS treatment (placebo)
Trial: 37533228
Drug: Long-term temozolomide
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term temozolomide (TMZ) treatment
Trial: 37533380
Drug: Trazpiroben (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazpiroben (all doses combined)
Trial: 37533418
Drug: Awareness of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Awareness of antibody response
Trial: 37533419
Drug: All booster
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All booster formulations
Trial: 37533588
Drug: Ketamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine treatment (serial intravenous infusions)